# Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

> **NCT00426712** · PHASE1 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 42 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen
- **BIOLOGICAL:** Hepatitis B Vaccine (Recombinant)

## Key facts

- **NCT ID:** NCT00426712
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00426712

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00426712, "Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00426712. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*